Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial saw people lose 12% of body weight.

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 percent of their body weight.

Eli Lilly's pill, orforglipron, is one step closer to becoming the first new, needle-free alternative in the booming market for weight loss and diabetes drugs.